8-KFinancial EventsRegulation FDExhibits & Filings

ABBOTT LABORATORIES 8-K Report, Exit or Disposal Costs (Jun 3, 2021)

Filed June 3, 2021For Securities:ABT

Summary

Abbott Laboratories (ABT) has filed an 8-K report detailing a significant restructuring plan impacting its COVID-19 diagnostic test manufacturing network. This plan is a direct response to evolving market dynamics, including reduced COVID-19 cases, accelerated vaccine rollouts, and updated guidance on testing for vaccinated individuals. The company anticipates incurring substantial pre-tax costs, estimated between $550 million and $700 million, primarily during the remainder of 2021, with a significant portion expected in the second quarter. These costs will encompass asset write-downs, inventory charges, and other exit-related expenses such as contract cancellations and employee costs. A notable portion of these charges ($320 million to $400 million) are non-cash. The company also disclosed an update to its 2021 financial outlook, providing non-GAAP adjusted diluted earnings per share, which excludes expenses related to restructuring and acquisitions. Investors should note the impact of these restructuring costs on near-term profitability while also considering the forward-looking financial guidance provided.

Key Highlights

  • 1Abbott is initiating a restructuring plan affecting its COVID-19 diagnostic test manufacturing network.
  • 2The plan is driven by decreased demand for COVID-19 testing due to lower case numbers, vaccine rollouts, and changes in testing guidance.
  • 3Estimated pre-tax restructuring costs range from $550 million to $700 million.
  • 4These costs are expected to be incurred mostly in the remainder of 2021, with a significant portion in Q2 2021.
  • 5Restructuring costs include fixed asset write-downs ($100M-$135M), inventory charges ($220M-$265M), and other exit costs ($230M-$300M).
  • 6Approximately $320 million to $400 million of the total estimated costs are non-cash charges.
  • 7The company has also updated its full-year 2021 financial outlook, providing non-GAAP adjusted earnings per share guidance.

Frequently Asked Questions

The restructuring is a response to significant changes in projected demand for COVID-19 diagnostic tests. Factors contributing to this include reduced COVID-19 cases, accelerated global vaccine distribution, and updated health authority guidance on testing for vaccinated individuals.

Abbott estimates pre-tax costs for this plan to be between $550 million and $700 million. The majority of these costs are expected to be recognized in the second quarter of 2021 and incurred throughout the remainder of 2021.

The costs include fixed asset write-downs, inventory-related charges, and other exit costs such as contract cancellations and employee-related expenses. Notably, a substantial portion of these costs ($320 million to $400 million) are non-cash charges.

Yes, Abbott issued a press release on June 1, 2021, providing an update to its financial outlook for the full year 2021. This outlook includes non-GAAP adjusted diluted earnings per share, which excludes items like restructuring expenses.